J&J: to collaborate with Evolve on child eczema drug
(CercleFinance.com) - Johnson & Johnson's Janssen is collaborating with Californian biotech firm Evolve BioSystems to conduct a clinical study in children at risk for developing atopic dermatitis, commonly known as eczema.
The study will assess the effects of introducing a specific gut bacterium in inhibiting the onset of atopic dermatitis, the most prevalent pediatric skin disorder, in the first year of life, the companies said.
Investigators will enroll infants who are less than 15 days old, with a genetic predisposition to allergic conditions, and will give them either daily single doses of a specific gut bacterium or a placebo for a 12-week period.
The patients will then be monitored for signs of atopic dermatitis, skin rash, diaper rash and itch over the next 2 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The study will assess the effects of introducing a specific gut bacterium in inhibiting the onset of atopic dermatitis, the most prevalent pediatric skin disorder, in the first year of life, the companies said.
Investigators will enroll infants who are less than 15 days old, with a genetic predisposition to allergic conditions, and will give them either daily single doses of a specific gut bacterium or a placebo for a 12-week period.
The patients will then be monitored for signs of atopic dermatitis, skin rash, diaper rash and itch over the next 2 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.